CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Researchers at Brigham and Women’s Hospital have developed a nasal spray that could provide broad-spectrum protection against ...

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...